van der Pol CC, Moelans CB, Manson QF, et al. - This study was attempted to investigate whether DDX3 is a useful prognosticator for male breast cancer (MBC) patients. Via immunohistochemistry, nuclear as well as cytoplasmic DDX3 expression was studied in a Dutch retrospective cohort of 106 MBC patients. Researchers examined differences in 10-year survival by DDX3 expression using a log-rank test. Uni- and multivariate Cox-regression analyses were conducted to evaluate the relationship between clinicopathologic variables, DDX3 expression, and survival. As per the results, cytoplasmic DDX3 expression appears to be a beneficial prognosticator in MBC, as high cytoplasmic DDX3 demonstrated better 10-year survival.